FLOW found a 24% lower hazard of its primary composite outcome with semaglutide versus placebo in adults with type 2 diabetes and chronic kidney disease. The outcome combined major kidney events and death from kidney-related or cardiovascular causes. The result does not mean a 24-percentage-point reduction in absolute risk or a 24% reduction in dialysis alone.

That distinction is the key to reading semaglutide kidney-disease headlines. Start with the enrolled population, the events being counted and the kind of comparison used.

What did the FLOW trial study?

The primary FLOW publication reports 3,533 randomized participants: 1,767 assigned to semaglutide and 1,766 to placebo. Participants had type 2 diabetes and defined chronic kidney disease, with kidney-function and albuminuria eligibility criteria. Median follow-up was 3.4 years. The trial stopped early after a prespecified interim analysis.

This was a clinical trial of a specified medicine added to a defined care setting. Its result is not evidence that an unrelated research material has the same effects, or that semaglutide replaces the rest of kidney and cardiovascular care.

What was included in the kidney composite?

The primary outcome counted time to a first qualifying event from this composite:

  • Kidney failure, including dialysis, kidney transplantation or an eGFR below 15 mL/min/1.73 m² under the trial definitions.
  • A reduction of at least 50% in eGFR from baseline.
  • Death from kidney-related or cardiovascular causes.

Because cardiovascular death is included, the primary result is not a kidney-only count. A component-specific estimate also cannot be read directly from the overall hazard ratio. The clinical trial endpoint guide explains why a composite, an individual event and a biomarker change answer different questions.

What does the 24% relative reduction mean?

FLOW reported a primary-outcome hazard ratio of 0.76, with a 95% confidence interval of 0.66–0.88. The familiar 24% figure comes from 1 − 0.76. It describes the relative event-hazard comparison over follow-up, not a subtraction of 24 percentage points from a person's risk.

Scroll horizontally to read all columns.

Primary composite outcomeSemaglutidePlacebo
Participants randomized1,7671,766
Participants with a first primary event331410
Observed event proportionAbout 18.7%: 331 ÷ 1,767.About 23.2%: 410 ÷ 1,766.

The simple difference between those observed proportions is approximately 4.5 percentage points. This calculation helps explain the difference between an absolute proportion and a relative hazard. It is not a standardized 3.4-year risk estimate: follow-up times varied, and the trial's primary analysis used time to an event. It is also not a result for dialysis alone or a prediction for an individual.

Do not add the separate component percentages to reconstruct the total. A participant can have more than one type of event over time, while a first-event composite counts that participant's first qualifying event once.

Did semaglutide improve eGFR in FLOW?

The study reported a less steep mean annual eGFR decline with semaglutide: a between-group difference of 1.16 mL/min/1.73 m² per year. “Slower decline” is the useful interpretation. It does not mean kidney function increased in every participant or that damaged kidneys were shown to regenerate.

Scroll horizontally to read all columns.

MeasureWhat it tells you
eGFR levelAn estimate of filtration at a stated assessment.
eGFR slopeHow that estimate changes over repeated assessments.
UACRUrinary albumin relative to creatinine in the sample.
Kidney-failure or composite eventWhether a defined clinical event occurred.

A favorable slope supports a different part of the evidence from an event count. Neither should replace the other in a summary, and a change in UACR is not numerically interchangeable with a change in eGFR.

Who do these results apply to?

FLOW directly studied people with both type 2 diabetes and the specified CKD eligibility features. It did not establish the same kidney benefit in people without diabetes, in every cause of kidney disease or in otherwise healthy people seeking general “kidney protection.” Those questions need evidence from their own populations.

A later FLOW analysis by CKD severity examined outcomes across baseline eGFR and albuminuria categories. It adds detail within the studied population; it is not a new independently randomized trial and does not expand the original eligibility to every disease setting. An imprecise subgroup estimate also should not be treated as proof that effects are identical in all groups.

Why the kidney benefit and acute kidney-injury warning can coexist

The current U.S. Ozempic prescribing information includes a warning about acute kidney injury due to volume depletion, including in the setting of gastrointestinal adverse reactions. That is a different question from the average long-term contrast in FLOW.

A favorable trial result does not remove product-specific risks, and a safety warning does not erase the trial result. Keep the population, product and time horizon attached to each statement. This article does not interpret a reader's laboratory results or recommend medication changes.

How FLOW differs from other semaglutide studies

The SELECT cardiovascular guide concerns an established cardiovascular-disease population without diabetes. The semaglutide plateau guide concerns weight trajectories and maintenance. Neither question should be substituted for FLOW's kidney composite.

Use the semaglutide dossier for broader molecular and trial context. To assess a kidney headline, ask: who was studied, which events were included, was the number relative or absolute, and what safety information remains relevant? Those four checks preserve the trial's findings without turning them into a universal promise.